Pumitamig + trastuzumab pamirtecan (T-Pam) in patients (pts) with HR+, HER2-low advanced/metastatic breast cancer (a/mBC): phase 1 results of a phase 1/2, open-label trial (BNT323-03) (EORTC-NCI-AACR 2026) - Sep 11, 2026 - Abstract #50; PB-050; Pres time: Nov 18, 2026; Location: Exhibition Hall; "Abstract will be available as of 4 November (with consent of the author)"
Clinical • Metastases • P1/2 data • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • HER-2
|